磁共振动态增强、弥散加权成像和波谱分析在肝脏局灶性病变的临床应用研究
|
摘要
第一部分磁共振动态增强在肝脏局灶性病变的临床应用研究
目的:利用Propeller LAVA动态增强扫描技术研究肝脏局灶性病变的的强化特点,以探讨其在肝脏局灶性病变中的应用价值。
方法:肝脏局灶性病变86例(原发性肝细胞癌51例,周围型胆管细胞癌2例,转移瘤5例,局灶性结节增生3例,血管瘤12例,囊肿7例,炎性病变6例),均行磁共振平扫(轴位T1WI,T2WI)和LAVA动态增强检查。扫描完成后,将LAVA原始图像推入ADW4.2工作站,采用最大信号强度投影、多平面重建和容积再现等重建肝动脉、门静脉和肝静脉。
结果:LAVA扫描成功率96.51%。原发性肝细胞癌主要表现为动脉期强化、门脉期和延迟期强化低于肝实质(84/126),动脉期强化、门脉期和延迟期强化与肝实质一致(20/126),动脉期和门脉期与肝实质一致、延迟期强化低于肝实质(14/126),部分病例可见供血动脉(16/126),包膜强化(67/126)且可以显示供血的门脉分支(8/126)和门脉瘤栓(5/49);周围型胆管癌表现为动脉期仅见肿瘤边缘不完整厚薄不均环状强化,门脉期和延迟期亦仅见周边环状强化(3/3);转移瘤表现为动脉期病灶周围环状强化(19/27)或无明显强化(8/27)、门脉期和延迟期均为环状强化,部分病灶仍然低于肝实质。局灶性结节增生各期均明显强化(3/3);血管瘤主要表现为由动脉期到延迟期造影剂由周边向中央填充(45/49);囊肿各期均无强化(34/34);炎性病变呈动脉期轻度环状强化,门脉期和延迟期环状强化更明显。
结论:不同肝脏局灶性病变的强化特点各不相同。结合平扫,磁共振动态增强则能提高对肝脏局灶性病变的诊断和鉴别诊断能力。
第二部分磁共振弥散加权成像在肝脏局灶性病变的临床应用
目的:利用磁共振弥散加权成像技术对肝脏局灶性病变进行定量分析,以探讨其在肝脏局灶性病变中的应用价值。
方法:正常肝脏10例和肝脏局灶性病变78例(原发性肝细胞癌28例,周围型胆管细胞癌1例,转移瘤15例,局灶性结节增生6例,血管瘤12例,囊肿11例,肝脓肿5例),采用EPI-SE DWI序列进行扫描,其中10例健康自愿者、10例肝细胞癌、5例局灶性结节增生、8例血管瘤和8例囊肿采用b=400、600、800、1000 s/mm2进行扫描,其余的均采用b=600 s/mm2扫描,扫描时间1分钟55秒。扫描完成后,推入工作站,测量DWI图像的信噪比,病变与肝脏的对比噪声比和病变的ADC值。
结果:b值与DWI图像信噪比存在显著负相关关系(r=-0.969,P=0.000),b值与肝癌、局灶性结节增生、血管瘤和囊肿与肝脏的对比噪声比存在显著负相关关系(r=-0.974,-0.921,-0.976,-0.969;P=0.000)。b值与肝癌、局灶性结节增生、血管瘤和囊肿的ADC值存在显著负相关关系(r=-0.784,-0.905,-0.968,-0.814;P=0.000)。当b值选用600 s/mm2时,肝癌、转移瘤、肝脓肿壁、局灶性结节增生、血管瘤和囊肿的ADC值分别为(0.86±0.29)×10-3 mm2/s、(0.91±0.23)×10-3 mm2/s、(1.22±0.49)×10-3 mm2/s、(1.52±0.36)×10-3 mm2/s、(2.39±0.41)×10-3 mm2/s和(3.22±0.17)×10-3 mm2/s。而正常肝脏的ADC值为(1.49±0.11) mm2/s。肝癌和转移瘤的ADC值小于正常肝脏(t=6.0363,7.8699;p=0.000),血管瘤和囊肿的ADC值大于肝脏(t=7.1761,29.1792;p=0.000)。肝脓肿壁和局灶性结节增生与肝脏的ADC值之间无统计学差异。肝癌与转移瘤的ADC值无统计学差异。当ADC值为1.15×10-3 mm2/s时,小于该值为恶性(阳性),大于等于该值为良性(阴性)诊断的一致百分比、敏感度和特异度分别为93.57%,92.23%和95.59%。
结论:依据磁共振弥散成像的DWI图像、ADC值及其变化规律,能比较准确的判断肝脏局灶性病变的性质,对其的诊断及鉴别诊断有一定价值。
第三部分磁共振波谱分析在肝脏局灶性病变鉴别诊断中的研究
目的:分析肝脏局灶性病变的磁共振波谱成像表现,以探讨其在肝脏局灶性病变鉴别诊断中的应用价值。
方法:肝脏局灶性病变64例(原发性肝细胞癌28例,周围型胆管细胞癌1例,转移瘤8例,局灶性结节增生6例,血管瘤12例,囊肿7例,肝脓肿2例),应用点分辨选择波谱技术行单体素扫描:TR=1265 ms,TE=144 ms,NEX=8,扫描时间1分11秒,每个患者分别采集病变区域及自体相对正常肝脏谱线。扫描完成后,应用SAGE软件测量谱线中cho峰高、cho峰下面积、lip峰高和lip峰下面积。
结果:肝癌的cho峰高和峰下面积明显高于自体非肿瘤组织(t=5.4026,4.7484;P=0.000,0.000),cho峰高/lip峰高和cho峰下面积/lip峰下面积高于自体非肿瘤组织(t=2.5711,2.1455;P=0.015,0.041);转移瘤的cho峰高和峰下面积明显高于自体非肿瘤组织(t=3.6583,8.9184;P=0.008,0.000);局灶性结节增生的lip峰高和峰下面积低于自体正常肝组织(t=-3.6581,-3.1700;P=0.020,0.025);血管瘤的cho峰高、lip峰高和峰下面积均明显低于正常肝组织(t=-4.4629,-5.9614,-3.1663;P=0.001,0.001,0.009),cho峰下面积/lip峰下面积明显高与正常肝组织(t=3.4237;P=0.006);囊肿的cho峰高、cho峰下面积、lip峰高和峰下面积均低于正常肝组织(t=-3.2498,-4.6134,-11.9062,-4.1326;P=0.0015,0.003,0.000,0.006),cho峰高/lip峰高和cho峰下面积/lip峰下面积高与正常肝组织(t=4.9298,2.9594;P=0.003,0.025);脓肿的cho峰低于对照,lip低于对照,cho/lip高于对照。恶性肿瘤组cho峰高、cho峰下面积、lip峰和lip峰下面积明显高于良性病变组(F=-5.2090,-5.4821,-4.9229,-5.4180;P=0.000,0.000,0.000,0.000),有显著统计学差异。
结论:磁共振质子波谱能在分子水平无创性地观察到肝脏局灶性病变的代谢异常,cho峰升高是恶性肿瘤的波谱特征,有助于良恶性肿瘤的鉴别诊断。
Part I Clincal application value of dynamic contrast enhanced MR scanning in the diagnosis of focal hepatic lesions.
Objective: To evaluate Propeller LAVA dynamic contrast enhanced MR scanning in the diagnosis of focal hepatic lesions.
Methods: 86 patients with focal hepatic lesions ( 51 hepatocellular carcinomas, 2 intrahepatic peripheral cholangiocarcinomas, 5 metastasises, 3 focal nodular hyperplasias, 12 hemangiomas, 7 hepatic cysts and 6 liver abscesses ) underwent conventional MR scanning ( T1WI and T2WI ) and Propeller LAVA dynamic contrast enhanced MR scanning. After the scanning ,the images were pushed into the workstation ADW 4.2 and then the hepatic artery , portal vein and hepatic vein were reconstructed by maximum intensity projection, multiplanner reconstruction and volume render.
Results: 84 of 126 HCC lesions showed strong enhancement in the arterial phase and washout in the portal venous phase and delay phase; 20 of 126 HCC lesions showed strong enhancement in the arterial phase and isointense to the surrounding hepatic parenchyma in the portal venous phase and delay phase; 14 of 126 HCC lesions were observed hypointense to the surrounding hepatic parenchyma only in the delay phase. The feeding artery(16/126), the pseudocapsule (67/126) and tumorthrombus in the portal vein(5/49)were seen in some case of HCC. The intrahepatic peripheral cholangiocarcinomas were observed slightly heterogeneous ring enhancement in the arterial phase and ring enhancement in the portal phase and delay phase. Metastasises were oberserved no enhancedment(19/27) or ring enhancement surrounding thelesions(8/27) in the arterial phase and ring enhancement in the portal enhancement and the delay phase. Focal nodular hyperplasias showed complete homogeneous hyperintense on early and delayed phase. 45 of 49 hemangiomas showed a nodular peripheral enhancement with centripetal filling in delayed phase plasias. The hepatic cysts showed no enhancement. The liver abscesses were observed slightly enhancement in the arterial phase and obvious ring enhancement in the portal phase and delay phase.
Conclusions: Various hepatic focal lesions have different enhancement patterns on the dynamic scans. Propeller LAVA dynamic contrast enhanced MR scanning is a useful method in diagnosis of focal liver lesions.
Part II Clincal application value of diffusion weighted imaging in the diagnosis of focal hepatic lesions.
Objective: To study the differential diagnosis value of diffusion-weighted imaging and apparent diffusion coefficient in focal hepatic lesions.
Methods: 10 healthy volunteers and 78 patients with focal hepatic lesions ( 28 hepatocellular carcinomas, 1 intrahepatic peripheral cholangiocarcinoma, 15 metastasises, 6 focal nodular hyperplasias, 12 hemangiomas, 11 hepatic cysts and 5 liver abscesses ) underwent DWI by using a SE-EPI sequence ( b=600 s/mm2 ) . Among of them, 10 healthy wolunteers ,10 hepatocellular carcinomas, 5 focal nodular hyperplasias, 8 hemangiomas, 8 hepatic cysts underwent DWI with four b value ( 400、600、800、1000 s/mm2 ). The scanning time was 1 min 55 s. After the scanning, the signal-to-noise ratio(SNR), contrast-to-noise(CNR) and apparent diffusion coefficient(ADC) value were calculated. Results: There were negative correlation between b value and the SNR of the healthy volunteers ( r = -0.969 ; P = 0.000 ) , between b value and the lesion-liver CNR ( hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, hepatic cyst ;r=-0.974,-0.921,-0.976,-0.969;P=0.000 ), beween b value and the ADC Value of focal hepatic lesion(hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, hepatic cysts ; r=-0.784,-0.905,-0.968,-0.814;P=0.000). when b was 600s/mm2 , the ADC values of primary hepatic carcinoma(PHC), metastasis, focal nodular hyperplasia, hemangioma, hepatic cyst and liver abscess were(0.86±0.29)×10-3 mm2/s、(0.91±0.23)×10-3 mm2/s、(1.22±0.49)×10-3 mm2/s、(1.52±0.36)×10-3 mm2/s、(2.39±0.41)×10-3 mm2/s and(3.22±0.17)×10-37 mm2/s, respectively. And the healthy volunteer was (1.49±0.11) mm2/s. ADC value of the PHC and metastasis was lower than that of the healthy volunteer. ADC value of the hemangioma and hepatic cyst was higher then that of the healthy volunteers. There were no statistic differences among focal nodular hyperplasia, hepatic cyst and the healthy volunteer. Use of a threshold ADC value less than 1.15×10-3 mm2/s for the diagnosis of malignant lesions resulted in sensitivity and specificity of 92.23% and 95.59%, respectively .
Conclusions: The focal hepatic lesions can be easily diagnosed and distinguished according to DWI, ADC value and their changing characteristics. So, DWI has an important clinical value in the diagnosis of focal hepatic lesions.
Part III Magnetic Resonance Spectroscopy Quantitative Analysis in the Differential diagnosis of focal hepatic lesions
Objective: To evaluate Magnetic Resonance Spectroscopy Quantitative Analysis in the diagnosis of focal hepatic lesions.
Methods: 64 patients with focal hepatic lesions ( 28 hepatocellular carcinomas, 1 intrahepatic peripheral cholangiocarcinoma, 8 metastasises, 6 focal nodular hyperplasias, 12 hemangiomas, 7 hepatic cysts and 2 liver abscesses ) underwent conventional MR scanning ( T1WI and T2WI ) and MRS scanning. Localized proton MR spectra with a voxel size of 8 were obtain in the focal hepatic lesions and in the hepatic parenchyma in the same patient as control. After volume-seletive autoshimming of the voxels, the spectra was obtained with a point-resolve spectroscopy technique ( TR=1265 ms, TE=144 ms,NEX=8,scan time 1 min 11 s) with water suppresion. And then the peak value and the area under the peak of cho and lip were caculated.
Result: Compared with the hepatic parenchyma ,The peak value and the area under the peak of cho in PHC was higher(t=5.4026,4.7484;P=0.000,0.000),the peak vule and the area under the peak of cho/lip was higher too(t=2.5711,2.1455;P=0.015,0.041);The peak value and the area under the peak of cho in metastasis was higher than the hepatic parenchyma(t=3.6583,8.9184;P=0.008,0.000); The the peak value and the area under the peak of lip in focal hepatic lesions was lower than the hepatic parenchyma(t=-3.6581,-3.1700;P=0.020,0.025); The the peak value of cho and lip and the area under the peak of lip in hemangioma was lowerr than the hepatic parenchyma(t=-4.4629,-5.9614,-3.1663;P=0.001,0.001,0.009), the area under the peak of cho/lip was higher then the hepatic parenchyma(t=3.4237,P=0.006); The cho and lip in hemangioma was lower than the hepatic parenchyma, the cho/lip was higher then the hepatic parenchyma.There was significent statistic difference between the malignant tumor and benign lesions in the peak value and the area under the peak of cho and lip(F=-5.2090,-5.4821,-4.9229,-5.4180;P=0.000,0.000,0.000,0.000).
Conclusions: MRS may show the metabolic changes in the focal hepatic lesions noninvasingly, and it is helpful for the differential diagnosis between benign and malignant lesions.
目的:利用Propeller LAVA动态增强扫描技术研究肝脏局灶性病变的的强化特点,以探讨其在肝脏局灶性病变中的应用价值。
方法:肝脏局灶性病变86例(原发性肝细胞癌51例,周围型胆管细胞癌2例,转移瘤5例,局灶性结节增生3例,血管瘤12例,囊肿7例,炎性病变6例),均行磁共振平扫(轴位T1WI,T2WI)和LAVA动态增强检查。扫描完成后,将LAVA原始图像推入ADW4.2工作站,采用最大信号强度投影、多平面重建和容积再现等重建肝动脉、门静脉和肝静脉。
结果:LAVA扫描成功率96.51%。原发性肝细胞癌主要表现为动脉期强化、门脉期和延迟期强化低于肝实质(84/126),动脉期强化、门脉期和延迟期强化与肝实质一致(20/126),动脉期和门脉期与肝实质一致、延迟期强化低于肝实质(14/126),部分病例可见供血动脉(16/126),包膜强化(67/126)且可以显示供血的门脉分支(8/126)和门脉瘤栓(5/49);周围型胆管癌表现为动脉期仅见肿瘤边缘不完整厚薄不均环状强化,门脉期和延迟期亦仅见周边环状强化(3/3);转移瘤表现为动脉期病灶周围环状强化(19/27)或无明显强化(8/27)、门脉期和延迟期均为环状强化,部分病灶仍然低于肝实质。局灶性结节增生各期均明显强化(3/3);血管瘤主要表现为由动脉期到延迟期造影剂由周边向中央填充(45/49);囊肿各期均无强化(34/34);炎性病变呈动脉期轻度环状强化,门脉期和延迟期环状强化更明显。
结论:不同肝脏局灶性病变的强化特点各不相同。结合平扫,磁共振动态增强则能提高对肝脏局灶性病变的诊断和鉴别诊断能力。
第二部分磁共振弥散加权成像在肝脏局灶性病变的临床应用
目的:利用磁共振弥散加权成像技术对肝脏局灶性病变进行定量分析,以探讨其在肝脏局灶性病变中的应用价值。
方法:正常肝脏10例和肝脏局灶性病变78例(原发性肝细胞癌28例,周围型胆管细胞癌1例,转移瘤15例,局灶性结节增生6例,血管瘤12例,囊肿11例,肝脓肿5例),采用EPI-SE DWI序列进行扫描,其中10例健康自愿者、10例肝细胞癌、5例局灶性结节增生、8例血管瘤和8例囊肿采用b=400、600、800、1000 s/mm2进行扫描,其余的均采用b=600 s/mm2扫描,扫描时间1分钟55秒。扫描完成后,推入工作站,测量DWI图像的信噪比,病变与肝脏的对比噪声比和病变的ADC值。
结果:b值与DWI图像信噪比存在显著负相关关系(r=-0.969,P=0.000),b值与肝癌、局灶性结节增生、血管瘤和囊肿与肝脏的对比噪声比存在显著负相关关系(r=-0.974,-0.921,-0.976,-0.969;P=0.000)。b值与肝癌、局灶性结节增生、血管瘤和囊肿的ADC值存在显著负相关关系(r=-0.784,-0.905,-0.968,-0.814;P=0.000)。当b值选用600 s/mm2时,肝癌、转移瘤、肝脓肿壁、局灶性结节增生、血管瘤和囊肿的ADC值分别为(0.86±0.29)×10-3 mm2/s、(0.91±0.23)×10-3 mm2/s、(1.22±0.49)×10-3 mm2/s、(1.52±0.36)×10-3 mm2/s、(2.39±0.41)×10-3 mm2/s和(3.22±0.17)×10-3 mm2/s。而正常肝脏的ADC值为(1.49±0.11) mm2/s。肝癌和转移瘤的ADC值小于正常肝脏(t=6.0363,7.8699;p=0.000),血管瘤和囊肿的ADC值大于肝脏(t=7.1761,29.1792;p=0.000)。肝脓肿壁和局灶性结节增生与肝脏的ADC值之间无统计学差异。肝癌与转移瘤的ADC值无统计学差异。当ADC值为1.15×10-3 mm2/s时,小于该值为恶性(阳性),大于等于该值为良性(阴性)诊断的一致百分比、敏感度和特异度分别为93.57%,92.23%和95.59%。
结论:依据磁共振弥散成像的DWI图像、ADC值及其变化规律,能比较准确的判断肝脏局灶性病变的性质,对其的诊断及鉴别诊断有一定价值。
第三部分磁共振波谱分析在肝脏局灶性病变鉴别诊断中的研究
目的:分析肝脏局灶性病变的磁共振波谱成像表现,以探讨其在肝脏局灶性病变鉴别诊断中的应用价值。
方法:肝脏局灶性病变64例(原发性肝细胞癌28例,周围型胆管细胞癌1例,转移瘤8例,局灶性结节增生6例,血管瘤12例,囊肿7例,肝脓肿2例),应用点分辨选择波谱技术行单体素扫描:TR=1265 ms,TE=144 ms,NEX=8,扫描时间1分11秒,每个患者分别采集病变区域及自体相对正常肝脏谱线。扫描完成后,应用SAGE软件测量谱线中cho峰高、cho峰下面积、lip峰高和lip峰下面积。
结果:肝癌的cho峰高和峰下面积明显高于自体非肿瘤组织(t=5.4026,4.7484;P=0.000,0.000),cho峰高/lip峰高和cho峰下面积/lip峰下面积高于自体非肿瘤组织(t=2.5711,2.1455;P=0.015,0.041);转移瘤的cho峰高和峰下面积明显高于自体非肿瘤组织(t=3.6583,8.9184;P=0.008,0.000);局灶性结节增生的lip峰高和峰下面积低于自体正常肝组织(t=-3.6581,-3.1700;P=0.020,0.025);血管瘤的cho峰高、lip峰高和峰下面积均明显低于正常肝组织(t=-4.4629,-5.9614,-3.1663;P=0.001,0.001,0.009),cho峰下面积/lip峰下面积明显高与正常肝组织(t=3.4237;P=0.006);囊肿的cho峰高、cho峰下面积、lip峰高和峰下面积均低于正常肝组织(t=-3.2498,-4.6134,-11.9062,-4.1326;P=0.0015,0.003,0.000,0.006),cho峰高/lip峰高和cho峰下面积/lip峰下面积高与正常肝组织(t=4.9298,2.9594;P=0.003,0.025);脓肿的cho峰低于对照,lip低于对照,cho/lip高于对照。恶性肿瘤组cho峰高、cho峰下面积、lip峰和lip峰下面积明显高于良性病变组(F=-5.2090,-5.4821,-4.9229,-5.4180;P=0.000,0.000,0.000,0.000),有显著统计学差异。
结论:磁共振质子波谱能在分子水平无创性地观察到肝脏局灶性病变的代谢异常,cho峰升高是恶性肿瘤的波谱特征,有助于良恶性肿瘤的鉴别诊断。
Part I Clincal application value of dynamic contrast enhanced MR scanning in the diagnosis of focal hepatic lesions.
Objective: To evaluate Propeller LAVA dynamic contrast enhanced MR scanning in the diagnosis of focal hepatic lesions.
Methods: 86 patients with focal hepatic lesions ( 51 hepatocellular carcinomas, 2 intrahepatic peripheral cholangiocarcinomas, 5 metastasises, 3 focal nodular hyperplasias, 12 hemangiomas, 7 hepatic cysts and 6 liver abscesses ) underwent conventional MR scanning ( T1WI and T2WI ) and Propeller LAVA dynamic contrast enhanced MR scanning. After the scanning ,the images were pushed into the workstation ADW 4.2 and then the hepatic artery , portal vein and hepatic vein were reconstructed by maximum intensity projection, multiplanner reconstruction and volume render.
Results: 84 of 126 HCC lesions showed strong enhancement in the arterial phase and washout in the portal venous phase and delay phase; 20 of 126 HCC lesions showed strong enhancement in the arterial phase and isointense to the surrounding hepatic parenchyma in the portal venous phase and delay phase; 14 of 126 HCC lesions were observed hypointense to the surrounding hepatic parenchyma only in the delay phase. The feeding artery(16/126), the pseudocapsule (67/126) and tumorthrombus in the portal vein(5/49)were seen in some case of HCC. The intrahepatic peripheral cholangiocarcinomas were observed slightly heterogeneous ring enhancement in the arterial phase and ring enhancement in the portal phase and delay phase. Metastasises were oberserved no enhancedment(19/27) or ring enhancement surrounding thelesions(8/27) in the arterial phase and ring enhancement in the portal enhancement and the delay phase. Focal nodular hyperplasias showed complete homogeneous hyperintense on early and delayed phase. 45 of 49 hemangiomas showed a nodular peripheral enhancement with centripetal filling in delayed phase plasias. The hepatic cysts showed no enhancement. The liver abscesses were observed slightly enhancement in the arterial phase and obvious ring enhancement in the portal phase and delay phase.
Conclusions: Various hepatic focal lesions have different enhancement patterns on the dynamic scans. Propeller LAVA dynamic contrast enhanced MR scanning is a useful method in diagnosis of focal liver lesions.
Part II Clincal application value of diffusion weighted imaging in the diagnosis of focal hepatic lesions.
Objective: To study the differential diagnosis value of diffusion-weighted imaging and apparent diffusion coefficient in focal hepatic lesions.
Methods: 10 healthy volunteers and 78 patients with focal hepatic lesions ( 28 hepatocellular carcinomas, 1 intrahepatic peripheral cholangiocarcinoma, 15 metastasises, 6 focal nodular hyperplasias, 12 hemangiomas, 11 hepatic cysts and 5 liver abscesses ) underwent DWI by using a SE-EPI sequence ( b=600 s/mm2 ) . Among of them, 10 healthy wolunteers ,10 hepatocellular carcinomas, 5 focal nodular hyperplasias, 8 hemangiomas, 8 hepatic cysts underwent DWI with four b value ( 400、600、800、1000 s/mm2 ). The scanning time was 1 min 55 s. After the scanning, the signal-to-noise ratio(SNR), contrast-to-noise(CNR) and apparent diffusion coefficient(ADC) value were calculated. Results: There were negative correlation between b value and the SNR of the healthy volunteers ( r = -0.969 ; P = 0.000 ) , between b value and the lesion-liver CNR ( hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, hepatic cyst ;r=-0.974,-0.921,-0.976,-0.969;P=0.000 ), beween b value and the ADC Value of focal hepatic lesion(hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, hepatic cysts ; r=-0.784,-0.905,-0.968,-0.814;P=0.000). when b was 600s/mm2 , the ADC values of primary hepatic carcinoma(PHC), metastasis, focal nodular hyperplasia, hemangioma, hepatic cyst and liver abscess were(0.86±0.29)×10-3 mm2/s、(0.91±0.23)×10-3 mm2/s、(1.22±0.49)×10-3 mm2/s、(1.52±0.36)×10-3 mm2/s、(2.39±0.41)×10-3 mm2/s and(3.22±0.17)×10-37 mm2/s, respectively. And the healthy volunteer was (1.49±0.11) mm2/s. ADC value of the PHC and metastasis was lower than that of the healthy volunteer. ADC value of the hemangioma and hepatic cyst was higher then that of the healthy volunteers. There were no statistic differences among focal nodular hyperplasia, hepatic cyst and the healthy volunteer. Use of a threshold ADC value less than 1.15×10-3 mm2/s for the diagnosis of malignant lesions resulted in sensitivity and specificity of 92.23% and 95.59%, respectively .
Conclusions: The focal hepatic lesions can be easily diagnosed and distinguished according to DWI, ADC value and their changing characteristics. So, DWI has an important clinical value in the diagnosis of focal hepatic lesions.
Part III Magnetic Resonance Spectroscopy Quantitative Analysis in the Differential diagnosis of focal hepatic lesions
Objective: To evaluate Magnetic Resonance Spectroscopy Quantitative Analysis in the diagnosis of focal hepatic lesions.
Methods: 64 patients with focal hepatic lesions ( 28 hepatocellular carcinomas, 1 intrahepatic peripheral cholangiocarcinoma, 8 metastasises, 6 focal nodular hyperplasias, 12 hemangiomas, 7 hepatic cysts and 2 liver abscesses ) underwent conventional MR scanning ( T1WI and T2WI ) and MRS scanning. Localized proton MR spectra with a voxel size of 8 were obtain in the focal hepatic lesions and in the hepatic parenchyma in the same patient as control. After volume-seletive autoshimming of the voxels, the spectra was obtained with a point-resolve spectroscopy technique ( TR=1265 ms, TE=144 ms,NEX=8,scan time 1 min 11 s) with water suppresion. And then the peak value and the area under the peak of cho and lip were caculated.
Result: Compared with the hepatic parenchyma ,The peak value and the area under the peak of cho in PHC was higher(t=5.4026,4.7484;P=0.000,0.000),the peak vule and the area under the peak of cho/lip was higher too(t=2.5711,2.1455;P=0.015,0.041);The peak value and the area under the peak of cho in metastasis was higher than the hepatic parenchyma(t=3.6583,8.9184;P=0.008,0.000); The the peak value and the area under the peak of lip in focal hepatic lesions was lower than the hepatic parenchyma(t=-3.6581,-3.1700;P=0.020,0.025); The the peak value of cho and lip and the area under the peak of lip in hemangioma was lowerr than the hepatic parenchyma(t=-4.4629,-5.9614,-3.1663;P=0.001,0.001,0.009), the area under the peak of cho/lip was higher then the hepatic parenchyma(t=3.4237,P=0.006); The cho and lip in hemangioma was lower than the hepatic parenchyma, the cho/lip was higher then the hepatic parenchyma.There was significent statistic difference between the malignant tumor and benign lesions in the peak value and the area under the peak of cho and lip(F=-5.2090,-5.4821,-4.9229,-5.4180;P=0.000,0.000,0.000,0.000).
Conclusions: MRS may show the metabolic changes in the focal hepatic lesions noninvasingly, and it is helpful for the differential diagnosis between benign and malignant lesions.
引文
1 Mahfouz AE, Hamm B, Taupitz M, et al1. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology, 1993, 186: 1332-1381.
2 Hussain SM, Zondervan PE, IJzermans JN , et al . Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics, 2002; 22 (5): 1023-1036.
3李晓娟,刘志兰,刘鹏飞,等.MR动态增强扫描对肝脏占位性病变的诊断价值.哈尔滨医科大学学报, 2005, 38(6): 576-576.
4赵英杰,邹杰.肝脏局灶性病变MR动态增强扫描的临床应用.中国临床医学影像杂志, 2000, 11(3):182-184.
5梁丽,马林,叶慧义,等.高压注射器在肝脏动态增强扫描中的应用.中国医学影像杂志,2000 ,8 (3)∶216-212.
6蹇素,杜勇,杨林,等.高压注射器对肝脏磁共振动态扫描应用研究.护士进修杂志,2005, 20(10): 885-886.
7 Vanden Bos IC, Hussain SM, Dwarkasing RS,et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging. 2007; 26(6): 1548-1555.
8. Kanematsu M, Semelka RC, Leonardou P , et al . Hepatocellular carcinoma of diffuse type : MR imaging findings and clinical manifestations. J Magn Reson Imaging, 2003, 18(2): 189-195.
9 Yamashita Y, Fan ZM, Yamamoto H, et al . Spin echo and dynamic gadolinium-enhanced FLASH MR imaging of hepatocellular carcinoma: correlation with histopathologic findings. J Magn Reson Imaging. 1994; 4(1): 83-90.
10李肃,徐坚民,李莹,等.肝细胞癌MR动态增强表现与病理的相关性研究.临床放射学杂志, 2002 , 21(12): 951-954.
11 Wang B, Gao ZQ ,Yan X, et al. Correlative Study of Angiogenesis and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Features of Hepatocellular Carcinoma. , 2005 , 46(4): 353-358.
12 Grazioli L, Olivetti L, Fugazzola C., et al. The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology Eur Radiol, 1999;9(1): 62-67.
13 Masaru K, Haranda T, Lovet JM, et al. Results of surgical for hepatocellular carcinoma: results of study on 125 patients. Hepatogastroenterology, 2001, 48: 1421-1424.
14 Worawattanakul S, Semelka RC, Noone TC, et al. Cholangiocarcinoma: spectrum of appearances on MR images using current techniques. Magn Reson Imaging, 1998, 16(9): 993-1003.
15 Nomura K, Kadoya M, Ueda K, et al. Detection of hepatic metastases from colorectal carcinoma: comparison of histopathologic features of anatomically resected liver with results of preoperative imaging. J Clin Gastroenterol. 2007, 41(8): 789-95.
16 Kanematsu M, Kondo H, Goshima S, et al. Imaging liver metastases: review and update. Eur J Radiol, 2006 , 58(2): 217-28.
17 Ito K, Cho ji T,N akada T, et al. Multislice dynamic MRI of hepatic tumors. JCA T, 1993, 17: 390-396.
18 Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions:characterisation with non-enhanced and dynamic contrast material-enhanced MR imaging. Radiol, 1994, 190: 417-423.
19 Nakamura H, M urakam i T, Ish ida T, et al. 3DTF-FISP MRI with gadopentetate dimeglumine in differential diagnosis of small liver tumo rs. JCA T, 1994, 18: 49- 54.
20 Martí-BonmatíL, Casillas C, DosdáR. Enhancement characteristics of hepatic focal nodular hyperplasia and its scar by dynamic magnetic resonance imaging. MAGMA, 2000, 10(3):200-204.
21 Li SJ, Ye HY, Du JB , et al . CT and MR imaging findings of focal nodular hyperplasiaof the liver. Chin J Med Imaging, 2004 ,12 (5) :344-347.
22 McFarland EG, Mayo-Smith WW, Saini S,et al. Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. Radiology. 1994 Oct;193(1):43-47
23 Hanafusa K, Ohashi I , HimenoY, et al . Hepatic hemangioma: findings with two-phase CT. Radiology , 1995 , 196 :465-469.
24 MorteléKJ, Ros PR. Cystic focal liver lesions in the adult: differential CT and MR imaging features. Radiographics, 2001, 21(4):895-910.
25 Jain R, Sawhney S, Bhargava DK, Hepatic granulomas due to visceral larva migrans in adults: appearance on US and MRI. Abdom Imaging. 1994 , 19(3): 253-256.
26张国福,周康荣,严福华,等.Gd-BOPTA增强MRI对小肝癌的诊断价值.临床放射学杂志, 2004, 23(12): 1052-1057.
27 Kajiwara M. MR imaging of small hepatocellular carcinoma (< or = 20 mm)--correlation with vascularity and histological features. Kurume Med J, 1997; 44(4): 327-338.
28 Krinsky GA, Lee VS, Theise ND, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl, 2002 , 8(12): 1156-1164.
29 Zhao H, Yao JL, Wang Y, et al. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J Gastroenterol. 2007, 13(8): 1252-1256.
30 Kanematsu M, Hoshi H, Murakami T, et al. Detection of hepatocellular carcinoma: comparison of low- and high-spatial-resolution dynamic MR images. AJR Am J Roentgenol,1999, 173(5): 1207-1212.
31 Mori K, Yoshioka H, Takahashi N, et al. Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging. AJR Am J Roentgenol, 2005 ,184(1):.63-69.
1 Chow LC , Bammer R , Moseley ME , et al. Single breath hold diffusion-weighted imaging of the abdomen. J Magn Reson Imaging, 2003 ,18(3) :377-382.
2 Boulanger Y, Amara M, Lepanto L , et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients . NMR Biomed , 2003 ,16(3) :132-136.
3 Chenevert TL , Brunberg JA , Pipe JG. Anisotropic diffusion in human white matter : demonstration with MR techniques i n vivo . Radiology ,1990 ,177 (2) : 401-405.
4祝新,王德杭,朱斌.磁共振弥散加权成像在肝占位病变中的应用.医学研究生学报, 2004, 17(10): 936-938.
5 Cieszanowski A, Szeszkowski W, Golebiowski M, et al. Discrimination of benign from malignant hepatic lesions based on their T2-relaxation times calculated from moderately T2-weighted turbo SE sequence. Eur Radiol, 2002 , 12(9): 2273-2279.
6 Ichikawa T, Haradome H, Hachiya J, et al. Diffusion-weighted MR imaging with a single-shot echo planar sequence : detection and characterization of focal hepatic lesions . Am J Roentgenol , 1998 ; 170 (2): 397-402.
7张刚,周翔平,刘荣波,等.弥散加权成像在肝脏局灶性病变的应用.四川大学博士论文,2005: 15-30.
8 Ichikawa T, Haradome H, Hachiya J, et al. Diffusion– weighted MR imaging with single - shot echo - p lanar imaging in the upper abdomen: p reliminary clinical experience in 61 patients. Abdom Imaging, 1999, 24 (5) : 456 - 461.
9 Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intra - voxel incohhrentmotion MR imaging. Radiology, 1988, 168 (2) : 497 - 450 .
10于德新,李传福,张晓明,等.3.0 T磁共振弥散成像对肝脏恶性局灶性病变诊断的价值.山东大学学报(医学版), 2006 ,44(5): 496-500.
11 Chan JH , Tsui EY, Luk SH , et al . Diffusion-weighted MR imaging of the liver : distinguishing hepatic abscess f rom cystic or necrotic tumor. Abdom Imaging , 2001 ; 26(2) : 161-165.
12李英,张晓鹏,唐磊,等.肝脏恶性肿瘤扩散加权成像与T2加权成像对比研究.中国医学影像技术, 2005 ; 21(12) : 1835-1838.
13 Gourtsoyianni S, Papanikolaou N, Yarmenitis S, et al. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol. 2008 ; 18(3) : 486-492.
14 Quan XY, Sun XJ, Yu ZJ, et al.Evaluation of diffusion weighted imaging of magnetic resonance imaging in small focal hepatic lesions: a quantitative study in 56 cases. Hepatobiliary Pancreat Dis Int. 2005 , 4(3) : 406-409.
15 Sun XJ, Quan XY, Huang FH, Quantitative evaluation of diffusion-weighted magnetic resonance imaging of focal hepatic lesions. World J Gastroenterol, 2005 , 11(41) : 6535-6537.
16郑建刚,许建兴,顾勇坚,等.磁共振弥散加权成像在肝局灶性病变中的价值.现代医药卫生, 2007, 23 (20): 3014-3016.
17 Demir OI, Obuz F, Sa?ol O, et al. Contribution of diffusion-weighted MRI to the differential diagnosis of hepatic masses Diagn Interv Radiol, 2007, 13(2): 81-86.
18 Taouli B , Vilgrain V , Dumont E , et al . Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR maging sequences : prospective study in 66 patient s. Radiology , 2003 ; 226 (1) :71-78.
19胡奕,郭启勇.背景抑制体部磁共振弥散加权成像在肝内局灶性病变诊断方面的应用价值研究.中国临床医学影像杂志, 2006 ; 17 (10)∶547-550.
1 Chan DC, Watts GF, Ng TW, et al. Measurement of liver fat by magnetic resonance imaging: Relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab, 2006, 8(6): 698-702.
2 Tarasów E, Wiercińska-Drapa?o A, Jaroszewicz J,et al. Metabolic disturbances in liver 1H MR spectroscopy in HIV and HCV co-infected patients as a potential marker of hepatocyte activation. Acta Radiol, 2004 , 45(8): 803-809.
3 Garbow JR, Lin X, Sakata N, et al. In vivo MRS measurement of liver lipid levels in mice. J Lipid Res, 2004 J, 45(7): 1364-1371.
4 van Laarhoven HW, Klomp DW, Kamm YJ, et al.In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. Cancer Res, 2003 , 63(22): 7609-7612.
5 McKenzie EJ, Jackson M, Sun J, et al. Monitoring the development of hepatocellular carcinoma in woodchucks using 31P-MRS. MAGMA, 2005 , 18(4): 201-5.
6张辉,李军东,王效春,等.正常青年人脑组织不同回波时间磁共振波谱分析.中国药物与临床,2005, 5 (11): 835-827.
7吴坚,叶慧义,孙非,等.肝细胞癌3.0T MR氢质子波谱的初步研究.中国医学影像技术.2006, 22(12): 1856-1859.
8 Ramin SL, Tognola WA, Spotti AR. Proton magnetic resonance spectroscopy: clinical applications in patients with brain lesions. Sao Paulo Med J, 2003 , 121(6): 254- 259.
9 Eugeniusz Tarasów, Leszek Siergiejczyk, Anatol Panasiuk, et al. MR proton spectroscopy in liver examinations of healthy individuals in vivo. Med Sci Monit, 2002; 8(2): MT36-40.
10张丽,胡道予,饶晶晶,等.正常人肝脏单体素1.5 T 1H-MRS的研究.放射学实践, 2007, 22(4): 391-394.
11 Thomas EL , Brynes AE , Hamilton G, et al . Hepatic Triglyceride Content and it sRelation to Body Adiposity : a Magnetic Resonance Imaging and Proton Magnetic Resonance Spect roscopy Study[J ] . Gut ,2005 ,54 (1) :122-127.
12 Thomas EL , Brynes AE , Hamilton G, et al . Effect of Nut ritional Counselling on Hepatic ,Muscle and Adipose Tissue Fat Content and Dist ribution in Non-alcoholic Fatty Liver Disease[J ] . World J Gastroenterol , 2006 , 12(36) : 5813-5819.
13 Ishimaru H , Morikawa M , Iwanaga S , et al . Differentiation between High-grade Glioma and Metastatic Brain Tumor Using Single-voxel Proton MR Spect roscopy [J ] . Eur Radiol , 2001 , 11(9) : 1784-1791.
14. Bates TE, Williams SR, Gadian DG. Phosphodiesters in the liver: the effect of field strength on the 31P signal. Magn Reson Med, 1989; 12: 145–50.
15 Keiko I. Proton MR spectroscopy of the brain with a focus on chemical issues[J ] . Magnetic Resonance in Medical Secience , 2003 , 3 : 117-132.
16 Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3T. Magn Reson Med, 2005 , 53(4): 770-776.
17 Soper R , Himmelreich U , Painter D , et al . Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spect roscopy and a statistical classification st rategy[J ] . Pathology , 2002 , 34(5) : 417-422.
18 Yoshikawa J , Mat sui O , Takashima T , et al . Fatty metamorphosis in hepatocellular carcinoma : radiologic features in 10 cases[J ] . AJ R ,1988 , 151 (4) : 717-720.
19 Ye HY, Zhao RF , Li YC , et al . MR imaging findings of hepatic tumors contained lipid[J ] . Chin J Med Imaging , 2004 , 12(5) : 340-343.
20 Kuo YT, Li CW, Chen CY, et al.In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging, 2004, 19(5): 598-604.
21 Dzik-Jurasz AS, Murphy PS, George M, et al. Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn Reson Med 2002; 47: 809–811.
22王钦习,于继徐,高玉庆,等.肝脏局灶性结节增生的MRI与病理对照性分析.医学影像学杂志, 2006, 16(3): 264-266.
23刘彤华.诊断病理学.北京:人民卫生出版社, 1995∶266-736.
1叶任高,陆再英.内科学(第五版).北京:人民卫生出版社, 2000. 471.
2胡道予.肝胆胰影像学诊断与介入治疗(第一版).武汉:湖北教育出版社, 2006. 124-178.
3 Doege CA, Kerskens CM, Romero BI, et al. MRI of small human stroke shows reversible diffusion changes in subcortical gray matter. Neuroreport, 2000 , 11(9): 2021-2024.
4 Harada M, Hisaoka S, Mori K, et al. Differences in water diffusion and lactate production in two different types of postinfectious encephalopathy. J Magn Reson Imaging, 2000, 11(5): 559-563.
5 Chow LC, Bammer R, Moseley ME, et al. Single breath-hold diffusion-weighted imaging of the abdomen. J Magn Reson Imaging, 2003, 18(3):377-382.
6 Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future Magn Reson Med Sci, 2005, 4(4): 175-186.
7 Ichikawa T , Haradome H , Hachiya J , et al . Diffusion-Weighted MR Imaging wit h a Single2Shot Echoplanar Sequence :Detection and Characterization of Focal Hepatic Lesions[J ] . AJ R, 1998, 170(2): 397-402.
8刘玉品,杨小庆.肝占位病变扩散加权成像的图像质量评价.实用放射学杂志, 2006, 22(8): 962-966.
9 Nasu K, Kuroki Y, Sekiguchi R, et al . Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med, 2006, 24(6): 438-444.
10 Coenegrachts K, Delanote J, Ter Beek L, et al.Improved focal liver lesion detection: comparison of single-shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol, 2007, 80(955): 524-531.
11 Hussain SM, De Becker J, Hop WC, et al. Can a single shot blackblood T2-weightedspin echo-planar imaging sequence with sensitivity encoding replace the respiratory-triggered turbo spinecho sequence for the liver? An optimization and feasibility study.J Magn Reson Imaging, 2005, 21: 219–229.
12 Quan XY, Sun XJ, Yu ZJ, et al.Evaluation of diffusion weighted imaging of magnetic resonance imaging in small focal hepatic lesions: a quantitative study in 56 cases. Hepatobiliary Pancreat Dis Int, 2005, 4(3): 406-409.
13 Gourtsoyianni S, Papanikolaou N, Yarmenitis S, et al. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol, 2008, 18(3): 486-492.
14李英,张晓鹏,唐磊,等.肝脏恶性肿瘤扩散加权成像与T2加权成像对比研究.中国医学影像技术, 2005 ; 21(12)∶1835-1838.
15 Inan N, Arslan A, Akansel G, et al. Diffusion-weighted imaging in the differential diagnosis of simple and hydatid cysts of the liver. AJR Am J Roentgenol, 2007 , 189(5): 1031-1036.
16 Chan JH , Tsui EY, Luk SH , et al . Diffusion-weighted MR imaging of the liver : distinguishing hepatic abscess f rom cystic or necrotic tumor. Abdom Imaging , 2001 ; 26 (2) : 161-165.
17 Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3T. Magn Reson Med, 2005, 53: 770–776.
18 Katz-Brull R, Rofsky NM, Lenkinski RE. Breathhold abdominal and thoracic proton MR spectroscopy at 3T. Magn Reson Med, 2003, 50(3): 461-467.
19 Patel N, Forton DM, Coutts GA, et al. Intracellular pH measurements of the whole head and the basal ganglia in chronic liver disease: a phosphorus-31 MR spectroscopy study. Metab Brain Dis, 2000, 15(3): 223-240.
20 Auricchio A, Zhou R, Wilson JM, et l. In vivo detection of gene expression in liver by 31P nuclear magnetic resonance spectroscopy employing creatine kinase as a marker gene.Proc Natl Acad Sci U S A, 2001, 98(9): 5205-5210.
21 Lim AK, Patel N, Hamilton G, et al. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology, 2003, 37(4): 788-794.
22 Chan DC, Watts GF, Ng TW, et al. Measurement of liver fat by magnetic resonance imaging: Relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab, 2006, 8(6): 698-702.
23 Tarasów E, Wiercińska-Drapa?o A, Jaroszewicz J,et al. Metabolic disturbances in liver 1H MR spectroscopy in HIV and HCV co-infected patients as a potential marker of hepatocyte activation. Acta Radiol, 2004, 45(8): 803-809.
24 Garbow JR, Lin X, Sakata N, et al. In vivo MRS measurement of liver lipid levels in mice. J Lipid Res, 2004, 45(7): 1364-1371.
25 Eugeniusz Tarasów, Leszek Siergiejczyk, Anatol Panasiuk, et al. MR proton spectroscopy in liver examinations of healthy individuals in vivo. Med Sci Monit, 2002, 8(2): MT36-40.
26. Bates TE, Williams SR, Gadian DG. Phosphodiesters in the liver: the effect of field strength on the 31P signal. Magn Reson Med, 1989; 12: 145–150.
27 Shah N, Sattar A, Benanti M, et al. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc, 2006, 106(1): 23-27.
28 Hascalik S, Celik O, Erdem G, et al. Proton magnetic resonance spectroscopy findings of a sacrococcygeal schwannoma. Int J Gynecol Cancer, 2006, Suppl 1: 344-348.
29 Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res, 2005, 24(4): 523-530.
30 Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer, 2006, 94(3): 427-435.
31 Bell JD, Cox IJ, Sargentoni J, et al. A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver.Biochim Biophys Acta, 1993, 1225: 71–77.
32 Soper R , Himmelreich U , Painter D , et al . Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spect roscopy and a statistical classification st rategy[J ] . Pathology , 2002 , 34(5) : 417-422.
33 Dzik-Jurasz AS, Murphy PS, George M, et al. Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn Reson Med 2002; 47: 809–811.
34 Kuo YT, Li CW, Chen CY, et al.In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging, 2004, 19(5): 598-604.
35 Bartha AI, Yap KR, Miller SP, et al. The normal neonatal brain: MR imaging, diffusion tensor imaging, and 3D MR spectroscopy in healthy termneonates. Am J Neuroradiol, 2007 ,28(6): 1015-1021.
36毕国力,包颜明,田伟.肝脏MR灌注成像的研究进展.国外医学临床放射学分册, 2007, 30(1): 38-41.
37 Fujita T, Ito K, Honjo K, et al. Hepatic parenchymal enhancement in the cirrhotic liver: evaluation by triple-phase dynamic MRI Abdom Imaging, 2002, 27(1): 29-33.
38 White MJ, O'Gorman RL, Charles-Edwards EM, et al. Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol, 2007, 80(950): 113-120.
39张皓,顾爱华,缪竞陶,等.正常肝脏MR灌注成像特点的分析.等实用放射学杂志, 2007, 23(3): 336-338.
40张铁宁,张皓,缪竞陶,等.MR灌注成像在肝脏常见占位性病变诊断及鉴别诊断中的价值初探.中国医学影像技术, 2006, 22(12): 1849-1852.
41 Miles KA , Hayball M , Dixon A K. Color perfusion imaging : a new application of computed tomography[J ] . Lancet ,1991 ,337 (8742) :643-645.
42 Guan S, Zhao WD, Zhou KR, et al. Assessment of hemodynamics in precancerous lesion of hepatocellular carcinoma: evaluation with MR perfusion World J Gastroenterol,2007, 13(8): 1182-1286.
43 Ichikawa T, Araki T. Fast magnetic resonance imaging of liver [J].Eur J Radiol, 1999, 29(3): 186- 210.
44 Taouli B, Losada M, Holland A, et al. Magnetic resonance imaging of hepatocellular carcinoma[J]. Gastroenterology, 2004,127(5 Suppl1): S144-152.
45 Yoshioka H, Takahashi N, Yamaguchi M, et al. Double arterial phase dynamic MRI with sensitivity encoding (SENSE) for hypervascular hepatocellular carcinomas[J]. J Magn Reson Imaging, 2002,16( 2): 259-266.
46 Hori M, Murakami T, Kim T, et al. Hemodynamic characterization of focal hepatic lesions: role of ferucarbotran-enhanced dynamic MR imaging using T2-weighted multishot spin-echo echo-planar sequence. J Magn Reson Imaging, 2006 , 23(4): 509-519.
47 Savranoglu P, Obuz F, Karasu S, et al. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging, 2006, 30(6): 377-381.
48 Tanimoto A, Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol, 2006, 58(2): 200-216.
49 Cheng WZ, Zeng MS, Yan FH, et al. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol, 2007, 13(36): 4891-4896.
50 Simon G, Link TM, W?rtler K, et al. Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol, 2005 , 15(5): 895-903.
51 Kim MJ, Kim JH, Chung JJ, et al. Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology, 2003, 228(3): 719-726.
52 Kim MJ, Kim JH, Choi JY, et al. Optimal TE for SPIO-enhanced gradient-recalled echo MRI for the detection of focal hepatic lesions. AJR Am J Roentgenol, 2006, 187(3): W255-266.
53 Zheng WW, Zhou KR, Chen ZW, et al. Characterization of focal hepatic lesions withSPIO-enhanced MRI. World J Gastroenterol, 2002, 8(1):82-86.
54 Poeckler-Schoeniger C, Koepke J,Gueckel F, et al. MRI with superparamagnetic iron oxide: efficacy in the detection and characterization of focal hepatic lesions. Magn Reson Imaging, 1999, 17(3): 383-392.
55 Tanimoto A, Wakabayashi G, Shinmoto H, et al.The mechanism of ring enhancement in hepatocellular carcinoma on superparamagnetic iron oxide-enhanced T1-weighted images: an investigation into peritumoral Kupffer cells. J Magn Reson Imaging, 2005, 21(3): 230-236.
56 Kumano S, Murakami T, Kim T, et al. Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions. AJR Am J Roentgenol, 2003,181(5): 1335-1359.
57 Macarini L, Marini S, Milillo P, et al. Double-contrast MRI (DC-MRI) in the study of the cirrhotic liver: utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions. Radiol Med (Torino), 2006, 111(8): 1087-1102.
58 Hanna RF, Kased N, Kwan SW, et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol, 2008 , 90(1): 47-57.
59 Glaser C. New techniques of cartilage imaging : T2 relaxation time and diffusion weighted MR imaging[J ] . Radiologic Cliniics of North America, 2005, 43 :641-653.
60 Cieszanowski A, Szeszkowski W, Golebiowski M, et al. Discrimination of benign from malignant hepatic lesions based on their T2-relaxation times calculated from moderately T2-weighted turbo SE sequence. Eur Radiol, 2002, 12(9): 2273-2279.
61 Chan YL, Lee SF, Yu SC, et al. Hepatic malignant tumour versus cavernous haemangioma: differentiation on multiple breath-hold turbo spin-echo MRI sequences with different T2-weighting and T2-relaxation time measurements on a single slice multi-echosequence. Clin Radiol, 2002, 57(4) :250-257.
62 Goldberg MA, Hahn PF, Saini S, et al. Value of T1 and T2 relaxation times from echoplanar MR imaging in the characterization of focal hepatic lesions. Am J Roentgenol, 1993, 160(5): 1011-1017.
63 Farraher SW, Jara H, Chang KJ, et al. Differentiation of hepatocellular carcinoma and hepatic metastasis from cysts and hemangiomas with calculated T2 relaxation times and the T1/T2 relaxation times ratio. J Magn Reson Imaging, 2006 , 24(6): 1333-1341.
2 Hussain SM, Zondervan PE, IJzermans JN , et al . Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics, 2002; 22 (5): 1023-1036.
3李晓娟,刘志兰,刘鹏飞,等.MR动态增强扫描对肝脏占位性病变的诊断价值.哈尔滨医科大学学报, 2005, 38(6): 576-576.
4赵英杰,邹杰.肝脏局灶性病变MR动态增强扫描的临床应用.中国临床医学影像杂志, 2000, 11(3):182-184.
5梁丽,马林,叶慧义,等.高压注射器在肝脏动态增强扫描中的应用.中国医学影像杂志,2000 ,8 (3)∶216-212.
6蹇素,杜勇,杨林,等.高压注射器对肝脏磁共振动态扫描应用研究.护士进修杂志,2005, 20(10): 885-886.
7 Vanden Bos IC, Hussain SM, Dwarkasing RS,et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging. 2007; 26(6): 1548-1555.
8. Kanematsu M, Semelka RC, Leonardou P , et al . Hepatocellular carcinoma of diffuse type : MR imaging findings and clinical manifestations. J Magn Reson Imaging, 2003, 18(2): 189-195.
9 Yamashita Y, Fan ZM, Yamamoto H, et al . Spin echo and dynamic gadolinium-enhanced FLASH MR imaging of hepatocellular carcinoma: correlation with histopathologic findings. J Magn Reson Imaging. 1994; 4(1): 83-90.
10李肃,徐坚民,李莹,等.肝细胞癌MR动态增强表现与病理的相关性研究.临床放射学杂志, 2002 , 21(12): 951-954.
11 Wang B, Gao ZQ ,Yan X, et al. Correlative Study of Angiogenesis and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Features of Hepatocellular Carcinoma. , 2005 , 46(4): 353-358.
12 Grazioli L, Olivetti L, Fugazzola C., et al. The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology Eur Radiol, 1999;9(1): 62-67.
13 Masaru K, Haranda T, Lovet JM, et al. Results of surgical for hepatocellular carcinoma: results of study on 125 patients. Hepatogastroenterology, 2001, 48: 1421-1424.
14 Worawattanakul S, Semelka RC, Noone TC, et al. Cholangiocarcinoma: spectrum of appearances on MR images using current techniques. Magn Reson Imaging, 1998, 16(9): 993-1003.
15 Nomura K, Kadoya M, Ueda K, et al. Detection of hepatic metastases from colorectal carcinoma: comparison of histopathologic features of anatomically resected liver with results of preoperative imaging. J Clin Gastroenterol. 2007, 41(8): 789-95.
16 Kanematsu M, Kondo H, Goshima S, et al. Imaging liver metastases: review and update. Eur J Radiol, 2006 , 58(2): 217-28.
17 Ito K, Cho ji T,N akada T, et al. Multislice dynamic MRI of hepatic tumors. JCA T, 1993, 17: 390-396.
18 Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions:characterisation with non-enhanced and dynamic contrast material-enhanced MR imaging. Radiol, 1994, 190: 417-423.
19 Nakamura H, M urakam i T, Ish ida T, et al. 3DTF-FISP MRI with gadopentetate dimeglumine in differential diagnosis of small liver tumo rs. JCA T, 1994, 18: 49- 54.
20 Martí-BonmatíL, Casillas C, DosdáR. Enhancement characteristics of hepatic focal nodular hyperplasia and its scar by dynamic magnetic resonance imaging. MAGMA, 2000, 10(3):200-204.
21 Li SJ, Ye HY, Du JB , et al . CT and MR imaging findings of focal nodular hyperplasiaof the liver. Chin J Med Imaging, 2004 ,12 (5) :344-347.
22 McFarland EG, Mayo-Smith WW, Saini S,et al. Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. Radiology. 1994 Oct;193(1):43-47
23 Hanafusa K, Ohashi I , HimenoY, et al . Hepatic hemangioma: findings with two-phase CT. Radiology , 1995 , 196 :465-469.
24 MorteléKJ, Ros PR. Cystic focal liver lesions in the adult: differential CT and MR imaging features. Radiographics, 2001, 21(4):895-910.
25 Jain R, Sawhney S, Bhargava DK, Hepatic granulomas due to visceral larva migrans in adults: appearance on US and MRI. Abdom Imaging. 1994 , 19(3): 253-256.
26张国福,周康荣,严福华,等.Gd-BOPTA增强MRI对小肝癌的诊断价值.临床放射学杂志, 2004, 23(12): 1052-1057.
27 Kajiwara M. MR imaging of small hepatocellular carcinoma (< or = 20 mm)--correlation with vascularity and histological features. Kurume Med J, 1997; 44(4): 327-338.
28 Krinsky GA, Lee VS, Theise ND, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl, 2002 , 8(12): 1156-1164.
29 Zhao H, Yao JL, Wang Y, et al. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J Gastroenterol. 2007, 13(8): 1252-1256.
30 Kanematsu M, Hoshi H, Murakami T, et al. Detection of hepatocellular carcinoma: comparison of low- and high-spatial-resolution dynamic MR images. AJR Am J Roentgenol,1999, 173(5): 1207-1212.
31 Mori K, Yoshioka H, Takahashi N, et al. Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging. AJR Am J Roentgenol, 2005 ,184(1):.63-69.
1 Chow LC , Bammer R , Moseley ME , et al. Single breath hold diffusion-weighted imaging of the abdomen. J Magn Reson Imaging, 2003 ,18(3) :377-382.
2 Boulanger Y, Amara M, Lepanto L , et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients . NMR Biomed , 2003 ,16(3) :132-136.
3 Chenevert TL , Brunberg JA , Pipe JG. Anisotropic diffusion in human white matter : demonstration with MR techniques i n vivo . Radiology ,1990 ,177 (2) : 401-405.
4祝新,王德杭,朱斌.磁共振弥散加权成像在肝占位病变中的应用.医学研究生学报, 2004, 17(10): 936-938.
5 Cieszanowski A, Szeszkowski W, Golebiowski M, et al. Discrimination of benign from malignant hepatic lesions based on their T2-relaxation times calculated from moderately T2-weighted turbo SE sequence. Eur Radiol, 2002 , 12(9): 2273-2279.
6 Ichikawa T, Haradome H, Hachiya J, et al. Diffusion-weighted MR imaging with a single-shot echo planar sequence : detection and characterization of focal hepatic lesions . Am J Roentgenol , 1998 ; 170 (2): 397-402.
7张刚,周翔平,刘荣波,等.弥散加权成像在肝脏局灶性病变的应用.四川大学博士论文,2005: 15-30.
8 Ichikawa T, Haradome H, Hachiya J, et al. Diffusion– weighted MR imaging with single - shot echo - p lanar imaging in the upper abdomen: p reliminary clinical experience in 61 patients. Abdom Imaging, 1999, 24 (5) : 456 - 461.
9 Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intra - voxel incohhrentmotion MR imaging. Radiology, 1988, 168 (2) : 497 - 450 .
10于德新,李传福,张晓明,等.3.0 T磁共振弥散成像对肝脏恶性局灶性病变诊断的价值.山东大学学报(医学版), 2006 ,44(5): 496-500.
11 Chan JH , Tsui EY, Luk SH , et al . Diffusion-weighted MR imaging of the liver : distinguishing hepatic abscess f rom cystic or necrotic tumor. Abdom Imaging , 2001 ; 26(2) : 161-165.
12李英,张晓鹏,唐磊,等.肝脏恶性肿瘤扩散加权成像与T2加权成像对比研究.中国医学影像技术, 2005 ; 21(12) : 1835-1838.
13 Gourtsoyianni S, Papanikolaou N, Yarmenitis S, et al. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol. 2008 ; 18(3) : 486-492.
14 Quan XY, Sun XJ, Yu ZJ, et al.Evaluation of diffusion weighted imaging of magnetic resonance imaging in small focal hepatic lesions: a quantitative study in 56 cases. Hepatobiliary Pancreat Dis Int. 2005 , 4(3) : 406-409.
15 Sun XJ, Quan XY, Huang FH, Quantitative evaluation of diffusion-weighted magnetic resonance imaging of focal hepatic lesions. World J Gastroenterol, 2005 , 11(41) : 6535-6537.
16郑建刚,许建兴,顾勇坚,等.磁共振弥散加权成像在肝局灶性病变中的价值.现代医药卫生, 2007, 23 (20): 3014-3016.
17 Demir OI, Obuz F, Sa?ol O, et al. Contribution of diffusion-weighted MRI to the differential diagnosis of hepatic masses Diagn Interv Radiol, 2007, 13(2): 81-86.
18 Taouli B , Vilgrain V , Dumont E , et al . Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR maging sequences : prospective study in 66 patient s. Radiology , 2003 ; 226 (1) :71-78.
19胡奕,郭启勇.背景抑制体部磁共振弥散加权成像在肝内局灶性病变诊断方面的应用价值研究.中国临床医学影像杂志, 2006 ; 17 (10)∶547-550.
1 Chan DC, Watts GF, Ng TW, et al. Measurement of liver fat by magnetic resonance imaging: Relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab, 2006, 8(6): 698-702.
2 Tarasów E, Wiercińska-Drapa?o A, Jaroszewicz J,et al. Metabolic disturbances in liver 1H MR spectroscopy in HIV and HCV co-infected patients as a potential marker of hepatocyte activation. Acta Radiol, 2004 , 45(8): 803-809.
3 Garbow JR, Lin X, Sakata N, et al. In vivo MRS measurement of liver lipid levels in mice. J Lipid Res, 2004 J, 45(7): 1364-1371.
4 van Laarhoven HW, Klomp DW, Kamm YJ, et al.In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. Cancer Res, 2003 , 63(22): 7609-7612.
5 McKenzie EJ, Jackson M, Sun J, et al. Monitoring the development of hepatocellular carcinoma in woodchucks using 31P-MRS. MAGMA, 2005 , 18(4): 201-5.
6张辉,李军东,王效春,等.正常青年人脑组织不同回波时间磁共振波谱分析.中国药物与临床,2005, 5 (11): 835-827.
7吴坚,叶慧义,孙非,等.肝细胞癌3.0T MR氢质子波谱的初步研究.中国医学影像技术.2006, 22(12): 1856-1859.
8 Ramin SL, Tognola WA, Spotti AR. Proton magnetic resonance spectroscopy: clinical applications in patients with brain lesions. Sao Paulo Med J, 2003 , 121(6): 254- 259.
9 Eugeniusz Tarasów, Leszek Siergiejczyk, Anatol Panasiuk, et al. MR proton spectroscopy in liver examinations of healthy individuals in vivo. Med Sci Monit, 2002; 8(2): MT36-40.
10张丽,胡道予,饶晶晶,等.正常人肝脏单体素1.5 T 1H-MRS的研究.放射学实践, 2007, 22(4): 391-394.
11 Thomas EL , Brynes AE , Hamilton G, et al . Hepatic Triglyceride Content and it sRelation to Body Adiposity : a Magnetic Resonance Imaging and Proton Magnetic Resonance Spect roscopy Study[J ] . Gut ,2005 ,54 (1) :122-127.
12 Thomas EL , Brynes AE , Hamilton G, et al . Effect of Nut ritional Counselling on Hepatic ,Muscle and Adipose Tissue Fat Content and Dist ribution in Non-alcoholic Fatty Liver Disease[J ] . World J Gastroenterol , 2006 , 12(36) : 5813-5819.
13 Ishimaru H , Morikawa M , Iwanaga S , et al . Differentiation between High-grade Glioma and Metastatic Brain Tumor Using Single-voxel Proton MR Spect roscopy [J ] . Eur Radiol , 2001 , 11(9) : 1784-1791.
14. Bates TE, Williams SR, Gadian DG. Phosphodiesters in the liver: the effect of field strength on the 31P signal. Magn Reson Med, 1989; 12: 145–50.
15 Keiko I. Proton MR spectroscopy of the brain with a focus on chemical issues[J ] . Magnetic Resonance in Medical Secience , 2003 , 3 : 117-132.
16 Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3T. Magn Reson Med, 2005 , 53(4): 770-776.
17 Soper R , Himmelreich U , Painter D , et al . Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spect roscopy and a statistical classification st rategy[J ] . Pathology , 2002 , 34(5) : 417-422.
18 Yoshikawa J , Mat sui O , Takashima T , et al . Fatty metamorphosis in hepatocellular carcinoma : radiologic features in 10 cases[J ] . AJ R ,1988 , 151 (4) : 717-720.
19 Ye HY, Zhao RF , Li YC , et al . MR imaging findings of hepatic tumors contained lipid[J ] . Chin J Med Imaging , 2004 , 12(5) : 340-343.
20 Kuo YT, Li CW, Chen CY, et al.In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging, 2004, 19(5): 598-604.
21 Dzik-Jurasz AS, Murphy PS, George M, et al. Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn Reson Med 2002; 47: 809–811.
22王钦习,于继徐,高玉庆,等.肝脏局灶性结节增生的MRI与病理对照性分析.医学影像学杂志, 2006, 16(3): 264-266.
23刘彤华.诊断病理学.北京:人民卫生出版社, 1995∶266-736.
1叶任高,陆再英.内科学(第五版).北京:人民卫生出版社, 2000. 471.
2胡道予.肝胆胰影像学诊断与介入治疗(第一版).武汉:湖北教育出版社, 2006. 124-178.
3 Doege CA, Kerskens CM, Romero BI, et al. MRI of small human stroke shows reversible diffusion changes in subcortical gray matter. Neuroreport, 2000 , 11(9): 2021-2024.
4 Harada M, Hisaoka S, Mori K, et al. Differences in water diffusion and lactate production in two different types of postinfectious encephalopathy. J Magn Reson Imaging, 2000, 11(5): 559-563.
5 Chow LC, Bammer R, Moseley ME, et al. Single breath-hold diffusion-weighted imaging of the abdomen. J Magn Reson Imaging, 2003, 18(3):377-382.
6 Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future Magn Reson Med Sci, 2005, 4(4): 175-186.
7 Ichikawa T , Haradome H , Hachiya J , et al . Diffusion-Weighted MR Imaging wit h a Single2Shot Echoplanar Sequence :Detection and Characterization of Focal Hepatic Lesions[J ] . AJ R, 1998, 170(2): 397-402.
8刘玉品,杨小庆.肝占位病变扩散加权成像的图像质量评价.实用放射学杂志, 2006, 22(8): 962-966.
9 Nasu K, Kuroki Y, Sekiguchi R, et al . Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med, 2006, 24(6): 438-444.
10 Coenegrachts K, Delanote J, Ter Beek L, et al.Improved focal liver lesion detection: comparison of single-shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol, 2007, 80(955): 524-531.
11 Hussain SM, De Becker J, Hop WC, et al. Can a single shot blackblood T2-weightedspin echo-planar imaging sequence with sensitivity encoding replace the respiratory-triggered turbo spinecho sequence for the liver? An optimization and feasibility study.J Magn Reson Imaging, 2005, 21: 219–229.
12 Quan XY, Sun XJ, Yu ZJ, et al.Evaluation of diffusion weighted imaging of magnetic resonance imaging in small focal hepatic lesions: a quantitative study in 56 cases. Hepatobiliary Pancreat Dis Int, 2005, 4(3): 406-409.
13 Gourtsoyianni S, Papanikolaou N, Yarmenitis S, et al. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol, 2008, 18(3): 486-492.
14李英,张晓鹏,唐磊,等.肝脏恶性肿瘤扩散加权成像与T2加权成像对比研究.中国医学影像技术, 2005 ; 21(12)∶1835-1838.
15 Inan N, Arslan A, Akansel G, et al. Diffusion-weighted imaging in the differential diagnosis of simple and hydatid cysts of the liver. AJR Am J Roentgenol, 2007 , 189(5): 1031-1036.
16 Chan JH , Tsui EY, Luk SH , et al . Diffusion-weighted MR imaging of the liver : distinguishing hepatic abscess f rom cystic or necrotic tumor. Abdom Imaging , 2001 ; 26 (2) : 161-165.
17 Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3T. Magn Reson Med, 2005, 53: 770–776.
18 Katz-Brull R, Rofsky NM, Lenkinski RE. Breathhold abdominal and thoracic proton MR spectroscopy at 3T. Magn Reson Med, 2003, 50(3): 461-467.
19 Patel N, Forton DM, Coutts GA, et al. Intracellular pH measurements of the whole head and the basal ganglia in chronic liver disease: a phosphorus-31 MR spectroscopy study. Metab Brain Dis, 2000, 15(3): 223-240.
20 Auricchio A, Zhou R, Wilson JM, et l. In vivo detection of gene expression in liver by 31P nuclear magnetic resonance spectroscopy employing creatine kinase as a marker gene.Proc Natl Acad Sci U S A, 2001, 98(9): 5205-5210.
21 Lim AK, Patel N, Hamilton G, et al. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology, 2003, 37(4): 788-794.
22 Chan DC, Watts GF, Ng TW, et al. Measurement of liver fat by magnetic resonance imaging: Relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab, 2006, 8(6): 698-702.
23 Tarasów E, Wiercińska-Drapa?o A, Jaroszewicz J,et al. Metabolic disturbances in liver 1H MR spectroscopy in HIV and HCV co-infected patients as a potential marker of hepatocyte activation. Acta Radiol, 2004, 45(8): 803-809.
24 Garbow JR, Lin X, Sakata N, et al. In vivo MRS measurement of liver lipid levels in mice. J Lipid Res, 2004, 45(7): 1364-1371.
25 Eugeniusz Tarasów, Leszek Siergiejczyk, Anatol Panasiuk, et al. MR proton spectroscopy in liver examinations of healthy individuals in vivo. Med Sci Monit, 2002, 8(2): MT36-40.
26. Bates TE, Williams SR, Gadian DG. Phosphodiesters in the liver: the effect of field strength on the 31P signal. Magn Reson Med, 1989; 12: 145–150.
27 Shah N, Sattar A, Benanti M, et al. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc, 2006, 106(1): 23-27.
28 Hascalik S, Celik O, Erdem G, et al. Proton magnetic resonance spectroscopy findings of a sacrococcygeal schwannoma. Int J Gynecol Cancer, 2006, Suppl 1: 344-348.
29 Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res, 2005, 24(4): 523-530.
30 Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer, 2006, 94(3): 427-435.
31 Bell JD, Cox IJ, Sargentoni J, et al. A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver.Biochim Biophys Acta, 1993, 1225: 71–77.
32 Soper R , Himmelreich U , Painter D , et al . Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spect roscopy and a statistical classification st rategy[J ] . Pathology , 2002 , 34(5) : 417-422.
33 Dzik-Jurasz AS, Murphy PS, George M, et al. Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn Reson Med 2002; 47: 809–811.
34 Kuo YT, Li CW, Chen CY, et al.In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging, 2004, 19(5): 598-604.
35 Bartha AI, Yap KR, Miller SP, et al. The normal neonatal brain: MR imaging, diffusion tensor imaging, and 3D MR spectroscopy in healthy termneonates. Am J Neuroradiol, 2007 ,28(6): 1015-1021.
36毕国力,包颜明,田伟.肝脏MR灌注成像的研究进展.国外医学临床放射学分册, 2007, 30(1): 38-41.
37 Fujita T, Ito K, Honjo K, et al. Hepatic parenchymal enhancement in the cirrhotic liver: evaluation by triple-phase dynamic MRI Abdom Imaging, 2002, 27(1): 29-33.
38 White MJ, O'Gorman RL, Charles-Edwards EM, et al. Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol, 2007, 80(950): 113-120.
39张皓,顾爱华,缪竞陶,等.正常肝脏MR灌注成像特点的分析.等实用放射学杂志, 2007, 23(3): 336-338.
40张铁宁,张皓,缪竞陶,等.MR灌注成像在肝脏常见占位性病变诊断及鉴别诊断中的价值初探.中国医学影像技术, 2006, 22(12): 1849-1852.
41 Miles KA , Hayball M , Dixon A K. Color perfusion imaging : a new application of computed tomography[J ] . Lancet ,1991 ,337 (8742) :643-645.
42 Guan S, Zhao WD, Zhou KR, et al. Assessment of hemodynamics in precancerous lesion of hepatocellular carcinoma: evaluation with MR perfusion World J Gastroenterol,2007, 13(8): 1182-1286.
43 Ichikawa T, Araki T. Fast magnetic resonance imaging of liver [J].Eur J Radiol, 1999, 29(3): 186- 210.
44 Taouli B, Losada M, Holland A, et al. Magnetic resonance imaging of hepatocellular carcinoma[J]. Gastroenterology, 2004,127(5 Suppl1): S144-152.
45 Yoshioka H, Takahashi N, Yamaguchi M, et al. Double arterial phase dynamic MRI with sensitivity encoding (SENSE) for hypervascular hepatocellular carcinomas[J]. J Magn Reson Imaging, 2002,16( 2): 259-266.
46 Hori M, Murakami T, Kim T, et al. Hemodynamic characterization of focal hepatic lesions: role of ferucarbotran-enhanced dynamic MR imaging using T2-weighted multishot spin-echo echo-planar sequence. J Magn Reson Imaging, 2006 , 23(4): 509-519.
47 Savranoglu P, Obuz F, Karasu S, et al. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging, 2006, 30(6): 377-381.
48 Tanimoto A, Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol, 2006, 58(2): 200-216.
49 Cheng WZ, Zeng MS, Yan FH, et al. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol, 2007, 13(36): 4891-4896.
50 Simon G, Link TM, W?rtler K, et al. Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol, 2005 , 15(5): 895-903.
51 Kim MJ, Kim JH, Chung JJ, et al. Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology, 2003, 228(3): 719-726.
52 Kim MJ, Kim JH, Choi JY, et al. Optimal TE for SPIO-enhanced gradient-recalled echo MRI for the detection of focal hepatic lesions. AJR Am J Roentgenol, 2006, 187(3): W255-266.
53 Zheng WW, Zhou KR, Chen ZW, et al. Characterization of focal hepatic lesions withSPIO-enhanced MRI. World J Gastroenterol, 2002, 8(1):82-86.
54 Poeckler-Schoeniger C, Koepke J,Gueckel F, et al. MRI with superparamagnetic iron oxide: efficacy in the detection and characterization of focal hepatic lesions. Magn Reson Imaging, 1999, 17(3): 383-392.
55 Tanimoto A, Wakabayashi G, Shinmoto H, et al.The mechanism of ring enhancement in hepatocellular carcinoma on superparamagnetic iron oxide-enhanced T1-weighted images: an investigation into peritumoral Kupffer cells. J Magn Reson Imaging, 2005, 21(3): 230-236.
56 Kumano S, Murakami T, Kim T, et al. Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions. AJR Am J Roentgenol, 2003,181(5): 1335-1359.
57 Macarini L, Marini S, Milillo P, et al. Double-contrast MRI (DC-MRI) in the study of the cirrhotic liver: utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions. Radiol Med (Torino), 2006, 111(8): 1087-1102.
58 Hanna RF, Kased N, Kwan SW, et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol, 2008 , 90(1): 47-57.
59 Glaser C. New techniques of cartilage imaging : T2 relaxation time and diffusion weighted MR imaging[J ] . Radiologic Cliniics of North America, 2005, 43 :641-653.
60 Cieszanowski A, Szeszkowski W, Golebiowski M, et al. Discrimination of benign from malignant hepatic lesions based on their T2-relaxation times calculated from moderately T2-weighted turbo SE sequence. Eur Radiol, 2002, 12(9): 2273-2279.
61 Chan YL, Lee SF, Yu SC, et al. Hepatic malignant tumour versus cavernous haemangioma: differentiation on multiple breath-hold turbo spin-echo MRI sequences with different T2-weighting and T2-relaxation time measurements on a single slice multi-echosequence. Clin Radiol, 2002, 57(4) :250-257.
62 Goldberg MA, Hahn PF, Saini S, et al. Value of T1 and T2 relaxation times from echoplanar MR imaging in the characterization of focal hepatic lesions. Am J Roentgenol, 1993, 160(5): 1011-1017.
63 Farraher SW, Jara H, Chang KJ, et al. Differentiation of hepatocellular carcinoma and hepatic metastasis from cysts and hemangiomas with calculated T2 relaxation times and the T1/T2 relaxation times ratio. J Magn Reson Imaging, 2006 , 24(6): 1333-1341.